Alnylam Pharmaceuticals vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Alnylam Pharmaceuticals (ALNY) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 14, 2026.
As of Aug 14, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Alnylam Pharmaceuticals trades at $227 versus a fair value of $51.70 (-77%), while Vertex Pharmaceuticals trades at $516 versus $279 (-46%).
Alnylam Pharmaceuticals
ALNY · USD · Health Care
-77%
upside to fair value
overvalued
Price$227
Fair Value$51.70
Quality66/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-46%
upside to fair value
overvalued
Price$516
Fair Value$279
Quality79/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Alnylam PharmaceuticalsVertex Pharmaceuticals
Valuation
70.9×P/E (TTM)28.8×
8.33×P/S (TTM)10.06×
45.25×P/B6.59×
43.5×EV/EBITDA23.8×
0.51×PEG1.72×
Profitability
13%Net margin36%
23%Operating margin38%
90%Return on equity24%
10%Return on assets12%
Growth
96%Revenue growth (YoY)8%
53.0%Avg. growth/yr (3Y)10.6%
49.8%Avg. growth/yr (5Y)14.2%
Balance & size
1.28×Debt / equity0.03×
$36BMarket cap$123B
healthyGrowth qualityhealthy
Vertex Pharmaceuticals leads: 6 to 7 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Alnylam Pharmaceuticalsof which business quality 63 · market factors 22Vertex Pharmaceuticalsof which business quality 77 · market factors 73
ProfitabilityMargins and returns on capital today
68
72
Quality GrowthAre margins and returns improving?
82
65
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
70
58
Low VolatilityCalm price path (market factor)
62
86
MomentumPrice trend over the last 3–12 months (market factor)
8
60
52W MomentumDistance to the 52-week high (market factor)
0
80
Net IssuanceBuybacks instead of dilution
36
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Alnylam Pharmaceuticals
DCF Models$99.63
Earnings-Based$82.25
Multiples$52.70
Asset-Based$3.96
Growth DCF$102
Economic Profit$37.29
Growth Earnings$109
24 of 24 models see the stock below the current price.
Vertex Pharmaceuticals
DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692
21 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Alnylam Pharmaceuticals
Bear $38.77Fair Value $51.70Bull $142
$227 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$516 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Alnylam Pharmaceuticals · Health Care
Quality score66 · Top 25%
Fair value upside-77% · bottom 25%
Vertex Pharmaceuticals · Health Care
Quality score79 · Top 25%
Fair value upside-46% · below median
Bottom line
As of Aug 14, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Alnylam Pharmaceuticals trades at $227 versus a fair value of $51.70 (-77%), while Vertex Pharmaceuticals trades at $516 versus $279 (-46%).
Vertex Pharmaceuticals has the higher quality score (79/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
